Expression and clinical significance of methyl‑CpG binding domain protein 2 in high‑grade serous ovarian cancer

Gong,Wangang; Ni,Maowei; Chen,Zhongbo; Zheng,Zhiguo

doi:10.3892/ol.2020.11836

Expression and clinical significance of methyl‑CpG binding domain protein 2 in high‑grade serous ovarian cancer

Authors:
- Wangang Gong
- Maowei Ni
- Zhongbo Chen
- Zhiguo Zheng
View Affiliations

Affiliations: College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: July 9, 2020 https://doi.org/10.3892/ol.2020.11836
Pages: 2749-2756
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platinum resistance is an important cause of clinical recurrence and mortality of patients with high‑grade serous ovarian cancer (HGSOC). Methyl‑CpG binding domain protein 2 (MBD2) serves an important role in tumor progression; however, its role in HGSOC remains unclear. The aim of the present study was to investigate the expression of MBD2 in HGSOC and its role in drug resistance and prognosis of HGSOC. MBD2 expression was analyzed by immunohistochemical staining and western blotting. The associations between MBD2 expression and clinical pathological features, platinum resistance and patient prognosis were analyzed using a χ2 test, Kaplan‑Meier analysis and Cox regression analysis. Positive MBD2 expression was detected in 73 (63.5%) of the HGSOC tissue samples, whereas it was undetectable in all 16 normal tissue samples (100%) analyzed, indicating a significantly higher expression level in tumor tissues compared with normal tissues (P<0.001). Additionally, MBD2 expression was significantly higher in platinum‑resistant cases compared with that in platinum‑sensitive cases (P<0.05). In addition, high expression of MBD2 was negatively associated with relapse‑free survival (P<0.05). In conclusion, MBD2 was demonstrated to be a potential drug target and a biomarker for poor prognosis in HGSOC.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration, . Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P and Ray-Coquard I: Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 89:207–216. 2014. View Article : Google Scholar : PubMed/NCBI
4	Lheureux S, Braunstein M and Oza AM: Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI
5	Wallace S, Kumar A, Mc Gree M, Weaver A, Mariani A, Langstraat C, Dowdy S, Bakkum-Gamez J and Cliby W: Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol. 145:21–26. 2017. View Article : Google Scholar : PubMed/NCBI
6	Li YC, Wang Y, Li DD, Zhang Y, Zhao TC and Li CF: Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer. J Cell Biochem. 119:2440–2449. 2018. View Article : Google Scholar : PubMed/NCBI
7	Parry L and Clarke AR: The roles of the methyl-CpG binding proteins in cancer. Genes Cancer. 2:618–630. 2011. View Article : Google Scholar : PubMed/NCBI
8	Defossez PA and Stancheva I: Biological functions of methyl-CpG-binding proteins. Prog Mol Biol Transl Sci. 101:377–398. 2011. View Article : Google Scholar : PubMed/NCBI
9	Stirzaker C, Song JZ, Ng W, Du Q, Armstrong NJ, Locke WJ, Statham AL, French H, Pidsley R, Valdes-Mora F, et al: Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer. Oncogene. 36:1328–1338. 2017. View Article : Google Scholar : PubMed/NCBI
10	Du Q, Luu PL, Stirzaker C and Clark SJ: Methyl-CpG-binding domain proteins: Readers of the epigenome. Epigenomics. 7:1051–1073. 2015. View Article : Google Scholar : PubMed/NCBI
11	Lai AY and Wade PA: Cancer biology and NuRD: A multifaceted chromatin remodelling complex. Nat Rev Cancer. 11:588–596. 2011. View Article : Google Scholar : PubMed/NCBI
12	Ramirez J, Dege C, Kutateladze TG and Hagman J: MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol Cell Biol. 32:5078–5088. 2012. View Article : Google Scholar : PubMed/NCBI
13	Cai Y, Geutjes EJ, de Lint K, Roepman P, Bruurs L, Yu LR, Wang W, van Blijswijk J, Mohammad H, de Rink I, et al: The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene. 33:2157–2168. 2014. View Article : Google Scholar : PubMed/NCBI
14	Tan CP and Nakielny S: Control of the DNA methylation system component MBD2 by protein arginine methylation. Mol Cell Biol. 26:7224–7235. 2006. View Article : Google Scholar : PubMed/NCBI
15	Fujita H, Fujii R, Aratani S, Amano T, Fukamizu A and Nakajima T: Antithetic effects of MBD2a on gene regulation. Mol Cell Biol. 23:2645–2657. 2003. View Article : Google Scholar : PubMed/NCBI
16	Zhu D, Hunter SB, Vertino PM and Van Meir EG: Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. Cancer Res. 71:5859–5870. 2011. View Article : Google Scholar : PubMed/NCBI
17	Pan ZX, Zhang XY, Chen SR and Li CZ: Upregulated exosomal miR-221/222 promotes cervical cancer via repressing methyl-CpG-binding domain protein 2. Eur Rev Med Pharmacol Sci. 23:3645–3653. 2019.PubMed/NCBI
18	Izquierdo-Torres E, Hernández-Oliveras A, Meneses-Morales I, Rodríguez G, Fuentes-García G and Zarain-Herzberg Á: Resveratrol up-regulates ATP2A3 gene expression in breast cancer cell lines through epigenetic mechanisms. Int J Biochem Cell Biol. 113:37–47. 2019. View Article : Google Scholar : PubMed/NCBI
19	Pontes TB, Chen ES, Gigek CO, Calcagno DQ, Wisnieski F, Leal MF, Demachki S, Assumpção PP, Artigiani R, Lourenço LG, et al: Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis. Tumour Biol. 35:3447–3453. 2014. View Article : Google Scholar : PubMed/NCBI
20	May S, Owen H, Phesse TJ, Greenow KR, Jones GR, Blackwood A, Cook PC, Towers C, Gallimore AM, Williams GT, et al: Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation. J Pathol. 245:270–282. 2018. View Article : Google Scholar : PubMed/NCBI
21	Liu W, Wang N, Lu M, Du XJ and Xing BC: MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection. Mol Med Rep. 14:1617–1623. 2016. View Article : Google Scholar : PubMed/NCBI
22	Mian OY, Wang SZ, Zhu SZ, Gnanapragasam MN, Graham L, Bear HD and Ginder GD: Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res. 9:1152–1162. 2011. View Article : Google Scholar : PubMed/NCBI
23	Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang C and Wu M: Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Gastroenterology. 145:853–864 e9. 2013. View Article : Google Scholar : PubMed/NCBI
24	Thul PJ and Lindskog C: The human protein atlas: A spatial map of the human proteome. Protein Sci. 27:233–244. 2018. View Article : Google Scholar : PubMed/NCBI
25	Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
26	Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, et al: A subcellular map of the human proteome. Science. 356:eaal33212017. View Article : Google Scholar : PubMed/NCBI
27	Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et al: A pathology atlas of the human cancer transcriptome. Science. 357:eaan25072017. View Article : Google Scholar : PubMed/NCBI
28	Zeppernick F and Meinhold-Heerlein I: The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014. View Article : Google Scholar : PubMed/NCBI
29	Zhang M, Liu T, Xia B, Yang C, Hou S, Xie W and Lou G: Platelet-derived growth factor D is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer. Int J Gynecol Cancer. 28:323–331. 2018. View Article : Google Scholar : PubMed/NCBI
30	Devailly G, Grandin M, Perriaud L, Mathot P, Delcros JG, Bidet Y, Morel AP, Bignon JY, Puisieux A, Mehlen P and Dante R: Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells. Nucleic Acids Res. 43:5838–5854. 2015. View Article : Google Scholar : PubMed/NCBI
31	Wood KH and Zhou Z: Emerging molecular and biological functions of MBD2, a reader of DNA methylation. Front Genet. 7:932016. View Article : Google Scholar : PubMed/NCBI
32	Mahmood N and Rabbani SA: DNA methylation readers and cancer: Mechanistic and therapeutic applications. Front Oncol. 9:4892019. View Article : Google Scholar : PubMed/NCBI
33	Le Guezennec X, Vermeulen M, Brinkman AB, Hoeijmakers WA, Cohen A, Lasonder E and Stunnenberg HG: MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol. 26:843–851. 2006. View Article : Google Scholar : PubMed/NCBI
34	Magdinier F and Wolffe AP: Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA. 98:4990–4995. 2001. View Article : Google Scholar : PubMed/NCBI
35	Cheng L, Tang Y, Chen X, Zhao L, Liu S, Ma Y, Wang N, Zhou K, Zhou J and Zhou M: Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells. Cancer Biol Ther. 19:676–686. 2018. View Article : Google Scholar : PubMed/NCBI
36	Alvarado S, Wyglinski J, Suderman M, Andrews SA and Szyf M: Methylated DNA binding domain protein 2 (MBD2) coordinately silences gene expression through activation of the microRNA hsa-mir-496 promoter in breast cancer cell line. PLoS One. 8:e740092013. View Article : Google Scholar : PubMed/NCBI
37	He M, Fan J, Jiang R, Tang WX and Wang ZW: Expression of DNMTs and MBD2 in GIST. Biomed Rep. 1:223–227. 2013. View Article : Google Scholar : PubMed/NCBI
38	Pei YF, Xu XN, Wang ZF, Wang FW, Wu WD, Geng JF and Liu XQ: Methyl-CpG binding domain protein 2 inhibits the malignant characteristic of lung adenocarcinoma through the epigenetic modulation of 10 to 11 translocation 1 and miR-200s. Am J Pathol. 189:1065–1076. 2019. View Article : Google Scholar : PubMed/NCBI
39	Berns EM and Bowtell DD: The changing view of high-grade serous ovarian cancer. Cancer Res. 72:2701–2704. 2012. View Article : Google Scholar : PubMed/NCBI
40	Huang RL, Gu F, Kirma NB, Ruan J, Chen CL, Wang HC, Liao YP, Chang CC, Yu MH, Pilrose JM, et al: Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics. 8:624–634. 2013. View Article : Google Scholar : PubMed/NCBI
41	Yu W, Jin C, Lou X, Han X, Li L, He Y, Zhang H, Ma K, Zhu J, Cheng L and Lin B: Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One. 6:e294502011. View Article : Google Scholar : PubMed/NCBI
42	Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, et al: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet. 386:249–257. 2015. View Article : Google Scholar : PubMed/NCBI
43	Tsuyoshi H, Orisaka M, Fujita Y, Asare-Werehene M, Tsang BK and Yoshida Y: Prognostic impact of dynamin related protein 1 (Drp1) in epithelial ovarian cancer. BMC Cancer. 20:4672020. View Article : Google Scholar : PubMed/NCBI
44	Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, et al: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 375:2154–2164. 2016. View Article : Google Scholar : PubMed/NCBI
45	Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L and Levine DA: Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun. 8:9902017. View Article : Google Scholar : PubMed/NCBI
46	Joueidi Y, Dion L, Bendifallah S, Mimoun C, Bricou A, Nyangoh Timoh K, Collinet P, Touboul C, Ouldamer L, Azaïs H, et al: Management and survival of elderly and very elderly patients with ovarian cancer: An age-stratified study of 1123 women from the FRANCOGYN group. J Clin Med. 9:14512020. View Article : Google Scholar
47	Scott LJ: Niraparib: First global approval. Drugs. 77:1029–1034. 2017. View Article : Google Scholar : PubMed/NCBI
48	Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, et al: Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: The MITO 15 trial. Ann Oncol. 27:487–493. 2016. View Article : Google Scholar : PubMed/NCBI
49	Fan XM, Zhang J, Niu SH, Li KX and Song CZ: Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases. Int J Surg. 38:61–66. 2017. View Article : Google Scholar : PubMed/NCBI
50	du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d'Investigateurs nationaux pour les etudes des cancers de l'Ovaire (GINECO). Cancer. 115:1234–1244. 2009. View Article : Google Scholar : PubMed/NCBI
51	E C, Li C, Li H and Yang J: Silencing of a novel lncRNA LOC105369748 suppresses the progression of hepatocellular carcinoma by sponging miR-5095 from MBD2. J Cell Physiol. 234:18504–18512. 2019. View Article : Google Scholar : PubMed/NCBI
52	Campbell PM, Bovenzi V and Szyf M: Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis. 25:499–507. 2004. View Article : Google Scholar : PubMed/NCBI
53	Giovinazzo H, Reichert ZR, Bergman A, Lin X, Wyhs N, Esopi D, Vaghasia A, Liu J, Jain Y, Bhamidipati A, et al: Abstract 5881: Novel inhibitors of the epigenetic reader protein MBD2. Cancer Res. 78 (Suppl 13):S58812018.